Abstract: Ketal compounds of the structure I and a method of preparation of the compound from polyols and oxocarboxylates, as well as uses thereof.

Abstract: Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, capsule shell control, basification and a reconstitution approach.

Abstract: Composite products and methods for making same are provided. The composite product can include a plurality of substrates and an at least partially cured binder composition. The binder composition, prior to curing, can include one or more tannins and one or more multifunctional aldehyde compounds. The one or more multifunctional aldehyde compounds can include (1) three or more carbon atoms and two or more aldehyde functional groups, or (2) two or more carbon atoms, at least one aldehyde functional group, and at least one functional group other than an aldehyde functional group. A carbon atom of at least one aldehyde functional group in the cured binder composition can have a first bond with a first tannin molecule and a second bond with (a) the first tannin molecule, (b) a second tannin molecule, or (c) an oxygen atom of the at least one aldehyde functional group.

Abstract: Composite products made with binder compositions that include one or more tannins, one or more multifunctional aldehydes, and one or more Lewis acids and methods for making same. The method can include contacting a plurality of substrates with the binder composition and at least partially curing the binder composition to produce a composite product. The one or more multifunctional aldehyde compounds can include (1) two or more carbon atoms and two or more aldehyde functional groups, or (2) two or more carbon atoms, at least one aldehyde functional group, and at least one functional group other than an aldehyde functional group. A carbon atom of at least one aldehyde functional group can have a first bond with a first tannin molecule and a second bond with (a) the first tannin molecule, (b) a second tannin molecule, or (c) an oxygen atom of the at least one aldehyde functional group.

Abstract: The invention relates to an extended release pharmaceutical composition comprising nevirapine.

Abstract: Annotation by search is described. In one aspect, a data store is searched for images that are semantically related to a baseline annotation of a given image and visually similar to the given image. The given image is then annotated with common concepts of annotations associated with at least a subset of the semantically and visually related images.

Abstract: The present disclosure relates to the preparation of ketal compounds from anhydropentitols and oxocarboxylates; derivatives, homopolymers, and copolymers thereof; and various compositions, formulations, and articles derived therefrom.

Abstract: The invention described herein provides a novel lactide monomer derivative and process for preparing the lactide monomer derivative. The monomer derivative of the invention is bifunctional in nature, and can be employed a variety of efficient synthesis processes to prepare various polymers. Further, the bifunctional monomer derivative can be used to prepare various intermediate-stage compounds and polymers, which in turn can be used to synthesize other compounds, polymers, copolymers and composites. The lactide monomer derivative has a bifunctional norbornene spiro lactide structure, spiro[6-methyl-1,4-dioxane-2,5-dione-3,2?-bicyclo[2.2.1]hept[5]ene], and structure as follows: and stereoisomers thereof. The lactide monomer derivative is bifunctional in that either 1) the norbornene ring, 2) lactide ring, or 3) both, can be opened and used in polymer synthesis for the backbone or the reactive branch for other polymeric syntheses.

Abstract: The present disclosure relates to the preparation of ketal compounds from anhydropentitols and oxocarboxylates; derivatives, homopolymers, and copolymers thereof; and various compositions, formulations, and articles derived therefrom.

Abstract: An ionic polymer of formula VI wherein each b=0 or 1; X is hydrogen, 1/z of a metal ion of charge z, a protonated nitrogen base, or a tetrasubstituted organic ammonium compound; the molar ratio of q:r:s:t=(100-0.1):(0-99.9):(0-50):(0-30); R1, R2 and R3 are hydrogen or C1-4 alkyl; R4, R5, R6 and R7 are hydrogen, C1-4 alkyl or F, wherein F is a functional group that imparts a property to polymer VI, at least one and no more than two of R4, R5, R6 and R7 are F and F is the same or different; G is a single bond or a C1-30 hydrocarbyl group; and for each instance of t when t is not zero, c=0-5 and d=0-5, provided that c+d=1-5, and wherein q, r and s as present in c are independent of any other value of q, r and s.

Abstract: A pharmaceutical composition of the following Compound (1), a potent hepatitis C viral (HCV) inhibitor, or a pharmaceutically acceptable salt thereof, for oral administration.

Abstract: A method for producing a product that comprises glycerol ketal of ethyl levulinate or propylene glycol ketal of ethyl levulinate comprises reacting either glycerol or propylene glycol with ethyl levulinate in the presence of a homogenous or heterogeneous catalyst system in a reactor system. The ethyl levulinate and either glycerol or propylene glycol are heated to remove water, polyol, and excess ethyl levulinate. The excess ethyl levulinate and polyol is recycled back to the reactor. The product is distilled in a specific fashion and optionally treated by means of a stabilizing agent or acid species removal bed, to obtain a composition comprising glycerol ketal of ethyl levulinate or propylene glycol ketal of ethyl levulinate wherein the composition comprises less than or equal to about 2 wt % contaminants.

Abstract: A polylactide copolymer comprises a graft copolymer of a hydrophobic backbone polymer having a plurality of pendant hydroxyl groups and lactide. In one example, a polylactide includes a graft copolymer of a poly(1,5-cyclooctadiene-co5-norbornene-2-methanol) copolymer and lactide. A method of preparing a toughened polylactide comprises forming a hydrophobic backbone copolymer having a plurality of pendant hydroxyl groups and forming a polylactide graft copolymer by reacting the hydrophobic backbone copolymer having a plurality of pendant hydroxyl groups with lactide, wherein polymerized lactide stems from at least one of the plurality of pendant hydroxyl groups.

Abstract: Disclosed is a pharmaceutical composition of a hepatitis C viral protease inhibitor which is suitable for oral administration via a liquid- or semi-solid-filled capsule and methods of using this composition for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The liquid- or semi-solid pharmaceutical composition of the present invention comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable lipids and hydrophilic surfactants.

Abstract: Compositions and methods for providing hydrophobic active agents in a bioavailable form are disclosed and described. In one aspect of the invention, pharmaceutical composition containing a testosterone ester is provided. The composition includes a testosterone ester in both dissolved form and as undissolved particles and the dissolved form comprises at least 35 wt % of the testosterone ester present in the composition. The composition further includes a solubilizer and a stabilizer.

Abstract: A homopolymer of 1,4-benzodioxepin-3-cyclohexyl-2,5-dione with a Tg of 120° C. Copolymers are also described. The polymers are useful for surgical and other applications where biodegradability is important.

Abstract: The present disclosure relates to the preparation of ketal compounds from polyols and oxocarboxylates, and uses thereof.

Abstract: A method and system for ranking content and providing a user interface for viewing the content is provided. The content system ranks content in a search result based on a combination of relevance of the content to a query and quality of the content. The content system may derive the quality of content by analyzing ratings provided by various content forums. The content system may use metadata provided by a content forum when searching for content that matches a query. The content system generates a rank score that combines the relevance and quality of the content and ranks the content according to the rank scores.

Abstract: The invention relates to an extended release pharmaceutical composition comprising nevirapine.

Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.